Wholesale Peptide Suppliers

Closed - No longer operating

Sterility assurance failure in compounded peptide injection product

Closed - None Known

Consistent product quality failures; 17 tested products averaged 6.3/10 purity/quantity score with minimum score of 0.0, indicating some products failed completely - Closed

Closed - No longer operating

FDA Class II recall (D-0093-2020) for Sermorelin Acetate 9mg/GHRP-2 5.4mg vials due to lack of assurance of sterility; recall initiated September 12, 2019 and terminated; nationwide distribution affected

Closed - No longer operating

Sterility assurance failures in compounded injectable solutions including SERMORELIN/GHRP-6/GHRP-2 formulations

Closed - FDA Class II Recall D-0776-2022 (April 5, 2022) for BPC-157 injectable formulation; reason: lack of assurance of sterility and CGMP deviations.

Closed (April 2022)

Closed - No longer operating

Lack of assurance of sterility; inadequate quality control processes identified during FDA inspection

Closed - FDA Class II Recall D-0447-2019, initiated December 17, 2018, for lack of assurance of sterility in compounded Thymosin Beta-4 injections; distributed nationwide.

Sterility assurance failure in compounded Thymosin Beta-4 product

Closed - None Known

Declining quality trend from B toward C grade; inconsistent product quality with wide variance in test results (4.6-10.0 range)

Closed - No longer operating

FDA Class II recall for Carnosine 5% ophthalmic drops due to lack of assurance of sterility; quality control process failures identified during FDA inspection

Closed - No longer operating

Non-sterile compounding resulting in microbial contamination

Closed - No longer operating

Compounded peptide product failed sterility assurance testing